ClinicalTrials.gov
public full text
Public Domain
Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib
Sunitinib is a chemotherapy approved by the FDA as a standard of care treatment for renal cell carcinoma (RCC). Fatigue is a very common side effect of sunitinib that frequently causes dose reductions. The cause of this fatigue remains unclear. This study will use a special type of scan to study sunitinib-induced fatigue in relation to exercise.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors#910344
- An Investigation of Light Therapy for Cancer-related Fatigue (The LITE Study)#1115023
- The Efficacy of Health Navigation® for Cancer-Related Fatigue in Cancer Survivors#803375
- Case Series: Can Daily Patient-Reported Outcome Measures Be Implemented for Cancer-Related Fatigue?#312704
- Efficacy and Safety of HRS9531 Tablet in Obese Subjects#844034
Record · ID 1162763
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive